The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress

Cancer Research

Volumn 73, Issue 11, 2013, Pages 3225-3234

  Sahm, Felix ^a,b   Oezen, Iris ^a,b   Opitz, Christiane A ^a,b   Radlwimmer, Bernhard ^a   Von Deimling, Andreas ^b   Ahrendt, Tilman ^c   Adams, Seray ^d   Bode, Helge B ^c   Guillemin, Gilles J ^d   Wick, Wolfgang ^a,b   Platten, Michael ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILATE 3,4 DIOXYGENASE; ALKYLATING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINATE NUCLEOTIDE PYROPHOSPHORYLASE (CARBOXYLATING); PHOSPHORIBOSYLTRANSFERASE; PROTEIN SYNTHESIS INHIBITOR; QUINOLINIC ACID; TEMOZOLOMIDE; TRYPTOPHAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTROCYTE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER TISSUE; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; GENE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MICROGLIA; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; QPRT GENE; RECURRENT CANCER; TRYPTOPHAN METABOLISM;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MICROGLIA; NAD; OXIDATIVE STRESS; PENTOSYLTRANSFERASES; QUINOLINIC ACID; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 84878595867     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3831     Document Type: Article

References (58)

1. PlattenM, WickW, Vanden EyndeBJ. Tryptophan catabolismincancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72:5435-40.
2. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumorinduced tolerance. J Clin Invest 2007;117:1147-54.
3. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
4. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 2005;65:8065-8.
5. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway.Am J Pathol 2010;176:2082-7.
6. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005;310:850-5.
7. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
8. Munn DH. Blocking IDOactivity to enhance anti-tumor immunity. Front Biosci 2012;4:734-45.
9. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proc Natl Acad Sci U S A 2012;109:2497-502.
10. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
11. Dolusic E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, et al. Tryptophan 2, 3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl) indoles as potential anticancer immunomodulators. J Med Chem 2011;54:5320-34.
12. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2, 3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005;49:15-23.
13. Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation 2009;6:36.
14. Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl 2006:285-304.
15. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG. Tryptophan metabolites and brain disorders. Clin Chem Lab Med 2003;41: 852-9.
16. Hassa PO. The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival. Front Biosci 2009;14:72-111.
17. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28.
18. Khan JA, Forouhar F, Tao X, Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Tar 2007;11:695-705.
19. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008; 26:45-51.
20. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42.
21. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009; 113:3276-86.
22. Magni G, Amici A, Emanuelli M, Raffaelli N, Ruggieri S. Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol 1999;73:135-82.
23. Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, et al. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res 2012;18:105-17.
24. Smythe GA, Poljak A, Bustamante S, Braga O, Maxwell A, Grant R, et al. ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. Adv Exp Med Biol 2003;527:705-12.
25. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, et al. High TGF beta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGFB gene. Cancer Cell 2007;11:147-60.
26. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 2011;128:1095-103.
27. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
28. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009;69: 9065-72.
29. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 1996;92:288-93.
30. Smith DG, Guillemin GJ, Pemberton L, Kerr S, Nath A, Smythe GA, et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol 2001;7:56-60.
31. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 2004;75:388-97.
32. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
33. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-15.
34. Wick W, Platten M, Weller M.New(alternative) temozolomide regimens for the treatment of glioma. Neuro-oncology 2009;11:69-79.
35. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
36. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011;129:659-70.
37. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 2003;54:388-92.
38. Zhai H, Heppner FL, Tsirka SE. Microglia/macrophages promote glioma progression. Glia 2011;59:472-85.
39. Ghosh A, Chaudhuri S. Microglial action in glioma: a boon turns bane. Immunol Lett 2010;131:3-9.
40. Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 2002;40:252-9.
41. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 2005;22:633-42.
42. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002;196:459-68.
43. Opitz CA, Wick W, Steinman L, Platten M. Tryptophan degradation in autoimmune diseases. Cell Mol Life Sci 2007;64:2542-63.
44. Ribeiro CA, Grando V, Dutra Filho CS, Wannmacher CM, Wajner M. Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem 2006;99:1531-42.
45. Inglis WL, Semba K. Discriminable excitotoxic effects of ibotenic acid, AMPA, NMDA and quinolinic acid in the rat laterodorsal tegmental nucleus. Brain Res 1997;755:17-27.
46. Pawley AC, Flesher S, Boegman RJ, Beninger RJ, Jhamandas KH. Differential action of NMDA antagonists on cholinergic neurotoxicity produced by N-methyl-D-aspartate and quinolinic acid. Br J Pharmacol 1996;117:1059-64.
47. Lehmann J, Schaefer P, Ferkany JW, Coyle JT. Quinolinic acid evokes [3H]acetylcholine release in striatal slices: mediation by NMDA-type excitatory amino acid receptors. Eur J Pharmacol 1983;96:111-5.
48. Grant R, Kapoor V. Inhibition of indoleamine 2, 3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels. Biochem Pharmacol 2003;66: 1033-6.
49. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism? Arch Biochem Biophys 1999;372:1-7.
50. Grant RS, Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 1998;70: 1759-63.
51. Grant RS, Naif H, Thuruthyil SJ, Nasr N, Littlejohn T, Takikawa O, et al. Induction of indoleamine 2, 3-dioxygenase in primary human macrophages by HIV-1. Redox Rep 2000;5: 105-7.
52. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001;78:842-53.
53. Espey MG, Chernyshev ON, Reinhard JF Jr, Namboodiri MA, Colton CA. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 1997;8:431-4.
54. Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocytederived macrophages. J Neuroimmunol 2001;120:190-8.
55. Guillemin GJ, Meininger V, Brew BJ. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:166-76.
56. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, et al. Characterization of the kynurenine pathway in human neurons. J Neurosci 2007;27:12884-92.
57. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 2011;71:2308-17.
58. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008;112:4193-201.